UBS lowered the firm’s price target on GoodRx (GDRX) to $5.25 from $6 and keeps a Neutral rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx Reports Strong Q1 2025 Results
- Positive Outlook on GoodRx Holdings: Strong Growth Potential and Strategic Positioning Justify Buy Rating
- Hold Rating for GoodRx Holdings Amid Revenue Challenges and Uncertainties
- GoodRx Earnings Call: Mixed Sentiment with Growth and Challenges
- GoodRx price target lowered to $4 from $4.75 at BofA
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue